Novo Nordisk面临降低销售预测、股票下跌以及一名新的CEO在毒品竞争中受到审查。 Novo Nordisk faces scrutiny over lowered sales forecasts, stock drop, and a new CEO amid drug competition.

诺沃诺迪斯克的投资者在公司降低其2025年的销售和利润前景后正面临审查,因为该公司的减重药品、Ozempic和Wegovy的竞争日益激烈。 Investors in Novo Nordisk are facing scrutiny after the company lowered its sales and profit outlook for 2025 due to increased competition for its weight-loss drugs, Ozempic and Wegovy. 这导致公司股票价格大幅下降。 This has led to a significant drop in the company's stock price. 律师事务所目前正在调查潜在的证券欺诈。 Law firms are now investigating potential securities fraud. 面对这些挑战,公司还任命了新的首席执行官Maziar Mike Doustdar。 The company also appointed a new CEO, Maziar Mike Doustdar, amid these challenges.